Showing 6 posts of 6 posts found.


Biosimilars: Can the US catch up in 2016?

February 12, 2016
Medical Communications, Sales and Marketing Eli Lilly, Enbrel, FDA, Neulasta, Novartis, Pfizer, Sandoz, Zarxio, biosimilars

What are biosimilars? Biosimilars are essentially the biological equivalent of generic drugs to their branded small-molecule counterparts (what Ibuprofen is …


Sandoz launches first US biosimilar

September 3, 2015
Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim

Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …

US Court blocks Novartis biosimilar Neupogen

May 8, 2015
Sales and Marketing Neupogen, Novartis, Zarxio, biosimilar, filagrastim, filgrastim-sndz

Novartis have been temporarily prevented from marketing its biosimilar version of Amgen’s drug Neupogen in the US. Earlier this year …

Novartis and Abbott start year with strong Q1 sales

April 23, 2015
Sales and Marketing Abbott, Amgen, Cosentyx, GSK, Neupogen, Novartis, Secukinumab, Zarxio, biosimilar, filgrastim, financials

Novartis and Abbott have both posted strong first-quarter results and made bullish predictions about their financial performance in 2015. Novartis …

Novartis image

Novartis secures first US biosimilar product

March 6, 2015
Research and Development, Sales and Marketing Amgen, Cancer, FDA, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, filgrastim-sndz

Novartis’ generic arm Sandoz has won the race to become the first company to market a biosimilar in the US …

Sandoz image

Sandoz earns historic first FDA biosimilar vote

January 8, 2015
Sales and Marketing FDA, Humira, Novartis, Sandoz, Zarxio, filgrastim, zarzio

Sandoz has taken a huge step forward in the race to be the first company to market a biosimilar in …

Latest content